Edition:
United States

Sinovac Biotech Ltd (SVA.OQ)

SVA.OQ on NASDAQ Stock Exchange Global Select Market

8.19USD
23 Feb 2018
Change (% chg)

$0.07 (+0.86%)
Prev Close
$8.12
Open
$8.12
Day's High
$8.20
Day's Low
$8.12
Volume
3,110
Avg. Vol
54,226
52-wk High
$8.58
52-wk Low
$4.60

Chart for

About

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1)... (more)
No analyst recommendations are available for .

Overall

Beta: 0.17
Market Cap(Mil.): $466.93
Shares Outstanding(Mil.): 57.01
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-Sinovac Provides Update On Going Private Transaction

* SINOVAC BIOTECH - EXPECTS TO FILE AMENDED GOING-PRIVATE STATEMENT, INCLUDING A DEFINITIVE PROXY STATEMENT AS AN EXHIBIT, WITH U.S. SEC IN DUE COURSE Source text for Eikon: Further company coverage:

Feb 07 2018

BRIEF-Sinovac Biotech Receives Positive Decision On Hepatitis A Vaccine From WHO

* SINOVAC BIOTECH RECEIVES POSITIVE DECISION ON ITS HEPATITIS A VACCINE FROM WORLD HEALTH ORGANIZATION

Dec 22 2017

BRIEF-Sinovac Biotech Announces Update On Nasdaq Matters

* SINOVAC BIOTECH- ‍NASDAQ HEARINGS PANEL GRANTED REQUEST TO EXTEND STAY OF SUSPENSION IN TRADING OF CO'S COMMON SHARES PENDING HEARING ON JAN 11, 2018​ Source text for Eikon: Further company coverage:

Nov 30 2017

BRIEF-Sinovac reports Q4 earnings per share $0.08

* Sinovac files 2016 annual report on form 20-F and reports unaudited fourth quarter 2016 financial results

Nov 22 2017

BRIEF-Sinovac Biotech receives delisting determination letter from Nasdaq

* Sinovac Biotech announces receipt of delisting determination letter from Nasdaq Source text for Eikon: Further company coverage:

Nov 03 2017

BRIEF-Sinobioway Consortium provides update on acquiring Sinovac Biotech at $8 per share

* Sinobioway Consortium provides update on acquiring Sinovac Biotech (Nasdaq: SVA) at the purchase price of $8 per share

Sep 29 2017

BRIEF-Sinovac Biotech preliminary phase III data shows Varicella vaccine was 87.1 pct efficacious against Chickenpox ​

* Sinovac reports preliminary top-line results from phase III clinical trial for Varicella vaccine candidate against Chickenpox

Sep 25 2017

Competitors

Earnings vs. Estimates